What is Affinia Therapeutics?
Affinia Therapeutics is a preclinical-stage biotechnology firm dedicated to the development of advanced gene therapies. By focusing on the rational design of therapeutic agents, the company aims to address the underlying causes of diverse medical conditions. Its market position is defined by a rigorous scientific approach that bridges the gap between fundamental biological discovery and clinical application. Operating out of Massachusetts, the company serves as a hub for innovation in the life sciences sector, specifically targeting diseases that have historically lacked effective treatment options.
How much funding has Affinia Therapeutics raised?
Affinia Therapeutics has raised a total of $223.3M across 4 funding rounds:
Series A
$60M
Series B
$110M
Series C
$40M
Private Equity
$13.3M
Series A (2020): $60M with participation from F-Prime Capital fprimecapital.com and New Enterprise Associates nea.com
Series B (2021): $110M led by Casdin Capital, Farallon, GV, Perceptive Advisors, TCG Crossover, Woodline Partners, Octagon Capital, RA Capital Management, and EcoR1 Capital
Series C (2025): $40M supported by Eli Lilly, GV, F-Prime Capital, Alexandria Venture Investments LLC Alexandria Venture Investments, Atlas Venture, and New Enterprise Associates
Private Equity (2025): $13.3M, investors not publicly disclosed
Key Investors in Affinia Therapeutics
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience.
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, with a strong focus on life sciences and frontier technology innovations.
F-Prime Capital
F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
What's next for Affinia Therapeutics?
With the recent capital injection, Affinia Therapeutics is well-positioned to accelerate its preclinical pipeline and transition toward critical clinical milestones. The strategic focus will likely center on scaling its manufacturing capabilities and expanding its research infrastructure to support the advancement of its lead candidates. As the company matures, the emphasis will shift toward navigating regulatory pathways and establishing partnerships that can facilitate the commercialization of its therapeutic portfolio. The ongoing support from top-tier venture capital firms suggests a long-term commitment to building a sustainable, high-impact enterprise in the gene therapy space.
See full Affinia Therapeutics company page
